^
Association details:
| Biomarker: | EGFR E746_A750del + KRAS amplification |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + LY3009120 (pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The combination of osimertinib with Raf inhibitor overcomes osimertinib resistance induced by KRAS amplification in EGFR-mutated lung cancer cells
Excerpt:
The EGFR-mutated NSCLC cell line, PC-9 (RRID: CVCL_B260), was used. PC-9 cells contain a deletion in exon 19 (delE746-A750) of EGFR...LY3009120, a RAF inhibitor, showed a significant synergistic effect with osimertinib on apoptotic cell death in osimertinib-resistant cells. Combined treatment with osimertinib and LY3009120 also demonstrated remarkable synergistic anti-tumor activity in mouse xenografts of these cells. This could be a potential new treatment option for KRAS amplification-induced osimertinib failure.
DOI:
https://doi.org/10.1016/j.yexcr.2023.113722
